| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
MILFORD, Mass.—Building on a two-year-old co-marketing partnership, Waters Corp. and Rosetta Biosoftware announced last month the integration of the Waters IdentityE search engine with the Rosetta Elucidator system. The integration extends the capabilities of the Elucidator system for Waters' customers by allowing MSE data generated on Waters' instrumentation to be processed qualitatively as well as quantitatively.

The announcement, made at the American Society for Mass Spectrometry (ASMS) conference in Denver last month, is the culmination of a collaboration that began in 2006 in which Rosetta imported and processed Waters' proteomics UPLC-MSE accurate mass data into its Elucidator system for relative quantification studies. Finding that the Elucidator system's quantitative study capabilities were useful to its customers but lacked the qualitative protein identification capabilities required by some researchers, the companies decided to upgrade data interrogation and visualization tools within the Elucidator system to leverage Waters' data format.

Tim Riley, vice president and managing director of Waters' Pharmaceutical Business Operations, says the integrated products create a "powerhouse solution" for both companies' proteomics customers.

"Both Waters and Rosetta Biosoftware firmly believe that robust informatics are absolutely critical to the meaningful interpretation of data from complex biological systems produced by state-of-the-art analytical instrumentation," Riley says.

Rosetta General Manager Yelena Shevelenko says the agreement is in line with both companies' commitment to provide flexible and interoperable software platforms for their customers.

"Collaboration with instrument vendors is a core strategy for Rosetta Biosoftware. Therefore, the partnership with Waters was a natural fit," Shevelenko says.

The Elucidator system allows users to organize, search for and retrieve raw and processed protein expression data. Users can incorporate organization-specific workflows into customized visual scripts that leverage Elucidator system statistical tools, customer-proprietary algorithms and information in the public domain.

IdentityE incorporates comprehensive peptide ion accounting informatics that visualize and identify peptides and proteins with a multi-layered physicochemical model of protein primary structure. The solution enables proteomics researchers to reference chromatographic retention time, exact precursor and product ion masses, structural significance, biological context and plausible detection of multiple peptides to identify a protein.

Customer response has been strong, as the integrated solution was used in a large number of presented studies at the ASMS conference, Shevelenko says.

"Our goal was to develop a revolutionary software product for proteomics researchers to enable their drug discovery efforts," she says. "We will continue to evaluate how we can collaborate to grow our individual and mutual goals of enabling researchers in the life science and drug discovery arena." DDN

About the Author

Related Topics

Published In

Volume 4 - Issue 7 | July 2008

July 2008

July 2008 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue